

# Coverage Possibilities for Life-Changing Therapies

Accessible high-quality coverage and care for gene therapies.

 The number of FDA approved gene therapies are increasing. **So should your coverage.**

Employer groups are facing a new challenge: how to offer access to these groundbreaking, life-saving treatments without exposing themselves to overwhelming financial risk. What was once considered impossible to treat or even manage is now a reality for patients, but without the right coverage, employers may find themselves unprepared.

## Here's How We're Solving This Challenge

The Association for CGT Solutions provides cost effective coverage for break-through treatments and avoidance of catastrophic claims.



**PEPM Cost: \$4.05**

## Comprehensive Financial Protection

- First-Dollar Coverage
- No Future Lasers
- Mitigates Stop Loss Renewal Increases
- Independent of Stop Loss Carrier

## Access to Integrated Care

- Credentialed Centers of Excellence
- Therapy and Administration Coverage
- Rare Disease Experienced Patient Navigator

impossible  
unaffordable  
inaccessible

The Association for CGT Solutions is committed to serving as your trusted partner to deliver education and solutions that address the financial and clinical complexities for gene therapies.

| Therapy                 | Therapeutic Coverage | Administration Coverage           |
|-------------------------|----------------------|-----------------------------------|
| Zolgensma®<br>Spinraza® | \$2,322,000          | \$27,500                          |
| Luxturna®               | \$850,000            | \$88,000                          |
| Zynteglo™               | \$2,800,000          | \$875,580                         |
| Skysona®                | \$3,000,000          | \$880,000                         |
| Elevidys™               | \$3,200,000          | \$28,600                          |
| Roctavian™              | \$2,900,000          | \$177,000                         |
| Hemgenix®               | \$3,500,000          | \$177,000                         |
| Casgevy™                | \$2,200,000          | \$658,000 SCD<br>\$875,580 β Thal |
| Lyfgenia™               | \$3,100,000          | \$658,000                         |
| Lenmeldy®               | \$4,250,000          | \$287,000                         |
| Kebilidi™               | \$3,950,000          | \$200,000                         |
| Zevaskyn™               | \$3,100,000          | \$767,000                         |



**Interested In Learning More?**

Contact Us, Today!

This document contains wording that was created by OutcomeRx.

© OutcomeRx Insurance Management Services, LLC 2025. All Rights Reserved.